Loading patent…
AssigneeJazz Pharmaceuticals International Limited
InventorsDavid J. ELLIS, George P. Miljanich, David E. Shields
Estimating the term…
The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl 1, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.
A method of administering an ω-conopeptide to a patient in need thereof for severe chronic pain, comprising administering to the patient a therapeutically effective amount of an ω-conopeptide thereof while avoiding admixture with an opioid, wherein said patient is also in need of therapy with the opioid.
The method according to claim 5, wherein said ziconotide is administered in a pharmaceutical composition comprising an antioxidant.
A method for treating severe chronic pain in a human patient, comprising:
Dependencies are inferred from the claim text.